Aug 28, 2025 9:15am EDT TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance
Aug 19, 2025 5:20pm EDT TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
Jun 24, 2025 9:15am EDT TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease
May 08, 2025 9:20am EDT TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
Apr 22, 2025 9:15am EDT TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
Apr 16, 2025 9:15am EDT TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025
Mar 17, 2025 9:15am EDT TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
Mar 05, 2025 9:00am EST TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
Feb 25, 2025 9:20am EST TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
Jan 29, 2025 9:15am EST TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
